BNKL SEC备案 - Bionik Laboratories Corp.- 年度报告、委托书、招股说明书

基本统计

CIK

1508381

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Bionik Laboratories Corp.

SEC Filings (Chronological Order)

本页提供了美国证券交易委员会（SEC）备案的完整、按时间顺序排列的列表，不包括我们在其他地方提供的所有权备案。

June 30, 2023	15-12G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 0-54717 BIONIK LABORATORIES CORP. (Exact name of registrant as specified in
June 27, 2023	8-K	BIONIK LABORATORIES CORP. (Exact Name of Registrant as Specified in Its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 22, 2023 BIONIK LABORATORIES CORP.
June 21, 2023	S-8 POS	As filed with the Securities and Exchange Commission on June 21, 2023 As filed with the Securities and Exchange Commission on June 21, 2023 Registration No.
June 21, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the Fiscal Year Ended March 31, 2023 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54717
June 16, 2023	EX-10.1	Form of Subscription Agreement Exhibit 10.1 SUBSCRIPTION AGREEMENT This Subscription Agreement (this “Agreement”) is made as of the date set forth on the signature page hereto, by and among Bionik Laboratories Corp., a Delaware corporation (the “Company”), and the subscriber or subscribers identified on the signature page(s) hereto (each, a “Subscriber” and collectively, the “Subscribers”). Recitals Whereas, on June 1, 2023, th
June 16, 2023	EX-10.3	Form of Promissory Note Exhibit 10.3 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM, THE REQUIREMENTS OF SUCH ACT OR SUCH LAWS. BIONIK LABORATORIES CORP. PROMISSORY NOTE Princ
June 16, 2023	8-K	BIONIK LABORATORIES CORP. (Exact Name of Registrant as Specified in Its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 9, 2023 BIONIK LABORATORIES CORP.
June 16, 2023	8-K	BIONIK LABORATORIES CORP. (Exact Name of Registrant as Specified in Its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 13, 2023 BIONIK LABORATORIES CORP.
June 16, 2023	EX-10.2	Form of Convertible Promissory Note Exhibit 10.2 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM, THE REQUIREMENTS OF SUCH ACT OR SUCH LAWS. BIONIK LABORATORIES CORP. CONVERTIBLE PROMISSOR
June 15, 2023	EX-99.1	Bionik Laboratories Expands its Partnership with Lifepoint Health with the Installation of InMotion® Robotic Devices at Four New Locations The completed installations in Arizona, California, Indiana, and Kentucky will bring advance stroke recovery ca Exhibit 99.1 Bionik Laboratories Expands its Partnership with Lifepoint Health with the Installation of InMotion® Robotic Devices at Four New Locations The completed installations in Arizona, California, Indiana, and Kentucky will bring advance stroke recovery care to Lifepoint Health patients. BOSTON, MA, June 15, 2023 – Bionik Laboratories Corp. (OTCPINK: BNKL) ("Bionik" or the "Company"), a rob
June 15, 2023	8-K	BIONIK LABORATORIES CORP. (Exact Name of Registrant as Specified in Its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 15, 2023 BIONIK LABORATORIES CORP.
May 31, 2023	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report BIONIK LABORATORIES CORP. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report BIONIK LABORATORIES CORP. (Exact name of registrant as specified in its charter) Delaware 000-54717 27-1340346 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 80 Coolidge Hill Road Watertown, MA 02472 (Address of pri
May 23, 2023	8-K	BIONIK LABORATORIES CORP. (Exact Name of Registrant as Specified in Its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 23, 2023 BIONIK LABORATORIES CORP.
May 23, 2023	EX-99.1	Bionik Laboratories Reports a Significant Increase in Patient Volume at its Acquired Rehabilitation Center in Florida Bionik’s first neuro-specialized rehabilitation clinic at Tower Physical Therapy & Rehab records significant patient growth, Bionik Exhibit 99.1 Bionik Laboratories Reports a Significant Increase in Patient Volume at its Acquired Rehabilitation Center in Florida Bionik’s first neuro-specialized rehabilitation clinic at Tower Physical Therapy & Rehab records significant patient growth, Bionik in advanced discussions regarding additional potential acquisitions BOSTON-(BUSINESS WIRE)-Bionik Laboratories Corp. (OTCPINK: BNKL), a r
May 4, 2023	EX-99.1	Bionik Laboratories Enters into Distribution Agreement with Pro-Med Technology for the Sale of InMotion® Robotic Devices in Hong Kong The agreement allows Bionik to further expand its footprint in Asia through Pro-Med’s sales and distribution network Exhibit 99.1 Bionik Laboratories Enters into Distribution Agreement with Pro-Med Technology for the Sale of InMotion® Robotic Devices in Hong Kong The agreement allows Bionik to further expand its footprint in Asia through Pro-Med’s sales and distribution network across Hong Kong MAY 4, 2023 - BOSTON, MA - Bionik Laboratories Corp. (OTCPINK: BNKL), a robotics company providing neurological functio
May 4, 2023	8-K	BIONIK LABORATORIES CORP. (Exact Name of Registrant as Specified in Its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 4, 2023 BIONIK LABORATORIES CORP.
April 26, 2023	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 20, 2023 BIONIK LABORATORIES CORP.
February 23, 2023	8-K	BIONIK LABORATORIES CORP. (Exact Name of Registrant as Specified in Its Charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 16, 2023 BIONIK LABORATORIES CORP.
February 23, 2023	EX-10.1	Subscription Agreement dated February 16, 2023 Exhibit 10.1 SUBSCRIPTION AGREEMENT This Subscription Agreement (this “Agreement”) is made as of the date set forth on the signature page hereto, by and among Bionik Laboratories Corp., a Delaware corporation (the “Company”), and the subscribers identified on the signature pages hereto (each, a “Subscriber” and collectively, the “Subscribers”). Recitals Whereas, in February 2023, the Company offer
February 23, 2023	EX-10.2	Convertible promissory Note dated February 16, 2023 Exhibit 10.2 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM, THE REQUIREMENTS OF SUCH ACT OR SUCH LAWS. BIONIK LABORATORIES CORP. CONVERTIBLE PROMISSOR
February 8, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 8, 2023 BIONIK LABORATORIES CORP.
February 8, 2023	EX-99.1	Bionik Laboratories Reports Third Quarter Fiscal Year 2023 Financial Results Nine Month Shipments and Revenue Exceeds 12-month Results of Prior Fiscal Year Exhibit 99.1 Bionik Laboratories Reports Third Quarter Fiscal Year 2023 Financial Results Nine Month Shipments and Revenue Exceeds 12-month Results of Prior Fiscal Year BOSTON – February 8, 2023 - Bionik Laboratories Corp. (OTCPINK: BNKL), a robotics company providing neurological functional recovery solutions to stroke survivors and others with functional and mobility challenges, offering its tec
February 8, 2023	EX-10.3	Subscription Agreement dated December 14, 2022 Exhibit 10.3 SUBSCRIPTION AGREEMENT This SUBSCRIPTION AGREEMENT (this “Agreement”) is made as of the date set forth on the signature page hereto, by and among BIONIK LABORATORIES CORP., a Delaware corporation (the “Company”), and the subscribers identified on the signature pages hereto (each, a “Subscriber” and collectively, the “Subscribers”). RECITALS WHEREAS, in December 2022, the Company comme
February 8, 2023	EX-10.4	Convertible Promissory Note dated December 14, 2022 Exhibit 10.4 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM, THE REQUIREMENTS OF SUCH ACT OR SUCH LAWS. BIONIK LABORATORIES CORP. SECURED CONVERTIBLE P
February 8, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 for the Quarterly Period ended December 31, 2022 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 for the transition period from to Commission File Number
January 20, 2023	8-K	Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 19, 2023 BIONIK LABORATORIES CORP.
December 20, 2022	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 14, 2022 BIONIK LABORATORIES CORP.
December 7, 2022	DEFA14A	Vstock Transfer, LLC 18 Lafayette Place Woodmere, New York 11598 * SPECIMEN * 1 MAIN STREET ANYWHERE PA 99999-9999 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
December 7, 2022	DEF 14A	BIONIK LABORATORIES CORP. NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JANUARY 19, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
November 17, 2022	EX-10.1	Subscription Agreement dated November 14, 2022 (incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on November 17, 2022) Exhibit 10.1 SUBSCRIPTION AGREEMENT This Subscription Agreement (this ?Agreement?) is made as of the date set forth on the signature page hereto, by and among Bionik Laboratories Corp., a Delaware corporation (the ?Company?), and the subscriber identified on the signature pages hereto (the ?Subscriber?). Recitals Whereas, the Subscriber wishes to purchase a Convertible Promissory Note in the form
November 17, 2022	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 14, 2022 BIONIK LABORATORIES CORP.
November 17, 2022	EX-10.2	Convertible Promissory Note dated November 14, 2022 (incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on November 17, 2022) Exhibit 10.2 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM, THE REQUIREMENTS OF SUCH ACT OR SUCH LAWS. BIONIK LABORATORIES CORP. SECURED CONVERTIBLE P
November 9, 2022	EX-99.1	Bionik Laboratories Reports Second Quarter Fiscal Year 2023 Financial Results Launch of Centers of Excellence Strategy Increases Outlook for Growth Exhibit 99.1 Bionik Laboratories Reports Second Quarter Fiscal Year 2023 Financial Results Launch of Centers of Excellence Strategy Increases Outlook for Growth BOSTON ? November 9, 2022 - Bionik Laboratories Corp. (OTCPink:BNKL), a robotics company providing neurological functional recovery solutions to stroke survivors and others with functional and mobility challenges, today reported financial
November 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 9, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 9, 2022 BIONIK LABORATORIES CORP.
November 7, 2022	EX-99.1	Bionik Laboratories to Present at the Q4 Virtual Investor Summit Presentation to be webcast at 9:00AM (ET), Monday, November 14, 2022 Exhibit 99.1 Bionik Laboratories to Present at the Q4 Virtual Investor Summit Presentation to be webcast at 9:00AM (ET), Monday, November 14, 2022 BOSTON, November 7, 2022 -(BUSINESS WIRE)- Bionik Laboratories Corp. (OTCPINK:BNKL) ("Bionik" or the "Company"), a robotics company providing neurological functional recovery solutions to stroke survivors and others with functional and mobility challeng
November 7, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 7, 2022 BIONIK LABORATORIES CORP.
November 4, 2022	EX-10.2	Secured Convertible Promissory Note dated September 2, 2022 Exhibit 10.2 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM, THE REQUIREMENTS OF SUCH ACT OR SUCH LAWS. BIONIK LABORATORIES CORP. SECURED CONVERTIBLE P
November 4, 2022	8-K/A	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A (Amendment No.
November 4, 2022	EX-10.3	Collateral Pledge Agreement dated September 2, 2022 Exhibit 10.3 COLLATERAL PLEDGE AGREEMENT THIS COLLATERAL PLEDGE AGREEMENT (this ?Agreement?), dated and effective as of the Effective Date, is by Bionik Laboratories Corp., a Delaware corporation with an address at 80 Coolidge Hill Road, Watertown, MA 02472 (the ?Parent?) and Bionik Inc., a Massachusetts corporation and the wholly-owned subsidiary of the Parent (the ?Pledgor?), in favor of GD HOLD
November 4, 2022	EX-10.1	Business Asset Purchase Agreement, dated August 30, 2022 Exhibit 10.1 BUSINESS ASSET PURCHASE AGREEMENT THIS AGREEMENT is made and entered by and between: BUYER: Legal Name of BUYER ("BUYER") Tower Aquatic LLC Individual [] Corporation [] Limited Liability Company [X] Partnership [] Other [] authorized agents or assigns. Address 80 Coolidge Hill Rd. City Watertown State MA Zip Code 02472 Mobile Phone 617-926-4800 Email [email protected] SELLER: Lega
October 13, 2022	EX-10.1	Amendment Agreement with Rich Russo Jr. (incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on October 13, 2022) Exhibit 10.1 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This Second Amendment (this ?Amendment?) to the Employment Agreement (the ?Original Agreement?) dated as of the Start Date (as defined in the Original Agreement), as amended pursuant to that First Amendment to Employment Agreement dated October 15, 2021 (the ?Amendment No. 1? and, with the Original Agreement, the ?Agreement?), by and between Bi
October 13, 2022	EX-99.1	Bionik Laboratories Appoints Richard Russo, Jr. as Chief Executive Officer and Dan Gonsalves as Chief Financial Officer Company continues to ramp up its recently announced growth strategy featuring ‘Centers of Excellence’ for Neuro-Recovery Care to b Exhibit 99.1 Bionik Laboratories Appoints Richard Russo, Jr. as Chief Executive Officer and Dan Gonsalves as Chief Financial Officer Company continues to ramp up its recently announced growth strategy featuring ?Centers of Excellence? for Neuro-Recovery Care to broaden access to robotic rehabilitation BOSTON, MA - October 13, 2022 - Bionik Laboratories Corp. (OTCPINK:BNKL) ("Bionik" or the "Compan
October 13, 2022	EX-10.2	Employment Agreement with Dan Gonsalves (incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on October 13, 2022) Exhibit 10.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT, is made as of the Start Date (as defined below), by and between BIONIK LABORATORIES CORP., a Delaware corporation (hereinafter referred to as the ?Company?), and Dan Gonsalves (hereinafter referred to as the ?Employee?). RECITALS WHEREAS, the Company, directly or through its subsidiaries, is engaged in the business of medical device rese
October 13, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 6, 2022 BIONIK LABORATORIES CORP.
September 8, 2022	EX-99.1	Bionik Laboratories Acquires Florida Rehabilitation Center; First in Strategic National Rollout Company’s specialized Neuro-Recovery Care Centers to showcase Bionik technology and solutions Exhibit 99.1 Bionik Laboratories Acquires Florida Rehabilitation Center; First in Strategic National Rollout Company’s specialized Neuro-Recovery Care Centers to showcase Bionik technology and solutions BOSTON, MA, September 8, 2022 - Bionik Laboratories Corp. (OTCPINK: BNKL) (“Bionik” or the “Company”), a robotics company providing neurological functional recovery solutions to stroke survivors an
September 8, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 8, 2022 BIONIK LABORATORIES CORP.
September 7, 2022	EX-10.3	Collateral Pledge Agreement dated September 2, 2022 Exhibit 10.3 COLLATERAL PLEDGE AGREEMENT THIS COLLATERAL PLEDGE AGREEMENT (this ?Agreement?), dated and effective as of the Effective Date, is by Bionik Laboratories Corp., a Delaware corporation with an address at 80 Coolidge Hill Road, Watertown, MA 02472 (the ?Parent?) and Bionik Inc., a Massachusetts corporation and the wholly-owned subsidiary of the Parent (the ?Pledgor?), in favor of GD HOLD
September 7, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 31, 2022 BIONIK LABORATORIES CORP.
September 7, 2022	EX-10.1	Business Asset Purchase Agreement, dated August 30, 2022 Exhibit 10.1 BUSINESS ASSET PURCHASE AGREEMENT THIS AGREEMENT is made and entered by and between: BUYER: Legal Name of BUYER ("BUYER") Tower Aquatic LLC Individual [] Corporation [] Limited Liability Company [X] Partnership [] Other [] authorized agents or assigns. Address 80 Coolidge Hill Rd. City Watertown State MA Zip Code 02472 Mobile Phone 617-926-4800 Email [email protected] SELLER: Lega
September 7, 2022	EX-10.2	Secured Convertible Promissory Note dated September 2, 2022 Exhibit 10.2 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM, THE REQUIREMENTS OF SUCH ACT OR SUCH LAWS. BIONIK LABORATORIES CORP. SECURED CONVERTIBLE P
September 1, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 1, 2022 BIONIK LABORATORIES CORP.
September 1, 2022	EX-99.1	BIONIK Laboratories to Present at National Investment Banking Association Conference Company focused on delivering long term value for investors Exhibit 99.1 BIONIK Laboratories to Present at National Investment Banking Association Conference Company focused on delivering long term value for investors BOSTON, MA, September 1, 2022 - BIONIK Laboratories Corp. (OTCPINK: BNKL) ("BIONIK" or the "Company"), a robotics company focused on providing rehabilitation and assistive technology solutions to stroke survivors and others with neurological
August 31, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 30, 2022 BIONIK LABORATORIES CORP.
August 16, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 16, 2022 BIONIK LABORATORIES CORP.
August 16, 2022	EX-99.1	INVESTOR PRESENTATION OTCPink: BNKL August 2022 Exhibit 99.1 INVESTOR PRESENTATION OTCPink: BNKL August 2022 OTCPink: BNKL Forward Looking Statements This document is private and confidential, and contains sensitive business information of BIONIK Laboratories Corp. (?BIONIK?) and is not for public distribution. This document has been prepared for informational purposes only and is provided personally to you. By accepting this document you agree
August 10, 2022	EX-99.1	BIONIK Laboratories Reports First Quarter Financial Results Exhibit 99.1 BIONIK Laboratories Reports First Quarter Financial Results BOSTON ? August 10, 2022 - BIONIK Laboratories Corp. (OTC Pink: BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today reported financial results for the first quarter of fiscal year 2023, ended June
August 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 10, 2022 BIONIK LABORATORIES CORP.
August 9, 2022	EX-99.1	BIONIK Laboratories Corp. to Present at Investor Summit Group’s Q3 Virtual Conference Presentation on Tuesday, August 16th at 2:45pm ET Exhibit 99.1 BIONIK Laboratories Corp. to Present at Investor Summit Group?s Q3 Virtual Conference Presentation on Tuesday, August 16th at 2:45pm ET BOSTON ? August 9, 2022 - BIONIK Laboratories Corp. (OTC Pink: BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today annou
August 9, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 9, 2022 BIONIK LABORATORIES CORP.
July 21, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 18, 2022 BIONIK LABORATORIES CORP.
July 21, 2022	EX-10.1	Severance Agreement and Release of All Claims with Loren Wass (incorporated by reference from the Company’s Current Report on Form 8-K filed with the SEC on July 21, 2022) EX-10.1 2 tm2221497d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SEVERANCE AGREEMENT AND RELEASE OF ALL CLAIMS This Severance Agreement and Release of All Claims (“Agreement”) is being entered into by and between Bionik Inc., a wholly owned subsidiary of Bionik Laboratories Corp. (the “Company”) with an address at 80 Coolidge Road, Watertown, MA 02472, and Loren Wass (“Employee”) 34 Webhannet Place, Kenn
July 6, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 29, 2022 BIONIK LABORATORIES CORP.
June 14, 2022	EX-10.2	Form of Convertible Promissory Note Exhibit 10.2 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM, THE REQUIREMENTS OF SUCH ACT OR SUCH LAWS. BIONIK LABORATORIES CORP. SECURED CONVERTIBLE P
June 14, 2022	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 9, 2022 BIONIK LABORATORIES CORP.
June 14, 2022	EX-10.1	Form of Subscription Agreement Exhibit 10.1 SUBSCRIPTION AGREEMENT This Subscription Agreement (this ?Agreement?) is made as of the date set forth on the signature page hereto, by and among Bionik Laboratories Corp., a Delaware corporation (the ?Company?), and the subscribers identified on the signature pages hereto (each, a ?Subscriber? and collectively, the ?Subscribers?). Recitals Whereas, in June 2022, the Company commenced
June 9, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 9, 2022 BIONIK LABORATORIES CORP.
June 9, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 9, 2022	EX-99.1	BIONIK Laboratories Reports Fourth Quarter and Fiscal Year 2022 Financial Results Exhibit 99.1 June 9, 2022 BIONIK Laboratories Reports Fourth Quarter and Fiscal Year 2022 Financial Results BOSTON ? June 9, 2022 - BIONIK Laboratories Corp. (OTCPink: BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today reported financial results for the fourth quarter
May 27, 2022	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report BIONIK LABORATORIES CORP. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report BIONIK LABORATORIES CORP. (Exact name of registrant as specified in its charter) Delaware 000-54717 27-1340346 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 80 Coolidge Hill Road Watertown, MA 02472 (Address of pri
April 6, 2022	8-K	Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 31, 2022 BIONIK LABORATORIES CORP.
February 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 for the Quarterly Period ended December 31, 2021 Or ☐ Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 for the transition period from to Commission File Number
February 9, 2022	EX-99.1	BIONIK Laboratories Reports Third Quarter Fiscal Year 2022 Financial Results Potential Sales Pipeline is Strongest in Corporate History Exhibit 99.1 February 9, 2022 BIONIK Laboratories Reports Third Quarter Fiscal Year 2022 Financial Results Potential Sales Pipeline is Strongest in Corporate History BOSTON ? February 9th, 2022 - BIONIK Laboratories Corp. (OTCQB: BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to
February 9, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 9, 2022 BIONIK LABORATORIES CORP.
December 20, 2021	8-K	Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 17, 2021 BIONIK LABORATORIES CORP.
November 17, 2021	DEF 14A	BIONIK LABORATORIES CORP. NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON DECEMBER 17, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
November 10, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 10, 2021	EX-99.1	BIONIK Laboratories Reports Second Quarter Fiscal Year 2022 Financial Results $5 Million Capital Raise Strengthens Balance Sheet EX-99.1 2 tm2132479d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 November 10, 2021 BIONIK Laboratories Reports Second Quarter Fiscal Year 2022 Financial Results $5 Million Capital Raise Strengthens Balance Sheet TORONTO & BOSTON – November 10, 2021 – BIONIK Laboratories Corp. (OTCQB:BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurol
November 10, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 10, 2021 BIONIK LABORATORIES CORP.
October 15, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 15, 2021 BIONIK LABORATORIES CORP.
October 15, 2021	EX-10.1	First Amendment to Employment Agreement with Rich Russo Jr. (Incorporated by reference to the Company’s Current Report on Form 8-K, filed on October 15, 2021) Exhibit 10.1 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment (this ?Amendment?) to the Employment Agreement (the ?Agreement?) dated as of the Start Date (as defined in the Agreement) by and between Bionik Laboratories Corp., a Delaware corporation, and Richard Russo, is made as of the 15th day of October, 2021, by and between the Company and the Employee (capitalized terms used herein
September 22, 2021	EX-99.1	BIONIK Laboratories Reports a 72% Increase in Patient Sessions on its InMotion® Robotic Devices Since Launch of InMotion Connect™ Platform Company also reports three consecutive quarters of patient session growth as U.S. healthcare facilities continu Exhibit 99.1 BIONIK Laboratories Reports a 72% Increase in Patient Sessions on its InMotion? Robotic Devices Since Launch of InMotion Connect? Platform Company also reports three consecutive quarters of patient session growth as U.S. healthcare facilities continue to adopt innovative technologies to accelerate stroke recovery TORONTO & BOSTON ? September 22, 2021 - BIONIK Laboratories Corp. (OTCQB
September 22, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 22, 2021 BIONIK LABORATORIES CORP.
August 12, 2021	EX-99.1	BIONIK Laboratories Reports Fiscal 2022 Q1 Financial Results Revenues Increase 160% Over Same Period in Prior Year $5M Capital Raise to Convert at $9.50/Share Showing Confidence in Bionik Exhibit 99.1 August 12, 2021 BIONIK Laboratories Reports Fiscal 2022 Q1 Financial Results Revenues Increase 160% Over Same Period in Prior Year $5M Capital Raise to Convert at $9.50/Share Showing Confidence in Bionik TORONTO & BOSTON - BIONIK Laboratories Corp. (OTCQB:BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological a
August 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 12, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 12, 2021 Bionik Laboratories Corp.
August 12, 2021	EX-10.1	Separation Agreement with Dr. Eric Dusseux, dated as of July 14, 2021 (Incorporated by reference to the Company’s Quarterly Report on Form 10-Q, filed on August 12, 2021) Exhibit 10.1 SEPARATION AGREEMENT This Separation Agreement (?Agreement?) is entered into as of July 14, 2021, by, between and among Dr. Eric Dusseux, an individual resident in France (?Dr. Dusseux?), Bionik Laboratories Inc., a corporation incorporated under the laws of Canada (?Bionik Canada?), and Bionik Laboratories Corp., a corporation incorporated under the laws of the state of Delaware (?Bi
July 29, 2021	EX-99.1	BIONIK Laboratories Announces $5 Million Capital Raise through Issuance of Convertible Notes Exhibit 99.1 BIONIK Laboratories Announces $5 Million Capital Raise through Issuance of Convertible Notes TORONTO & BOSTON - July 29, 2021- BIONIK Laboratories Corp. (OTCQB:BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, announced today it has entered into a series of ag
July 29, 2021	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 26, 2021 Bionik Laboratories Corp.
July 21, 2021	EX-10.2	Form of Convertible Promissory Note (Incorporated by reference to the Company’s Current Report on Form 8-K, filed on July 21, 2021) Exhibit 10.2 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM, THE REQUIREMENTS OF SUCH ACT OR SUCH LAWS. BIONIK LABORATORIES CORP. SECURED CONVERTIBLE P
July 21, 2021	EX-10.1	Form of Subscription Agreement Exhibit 10.1 SUBSCRIPTION AGREEMENT This Subscription Agreement (this ?Agreement?) is made as of the date set forth on the signature page hereto, by and among Bionik Laboratories Corp., a Delaware corporation (the ?Company?), and the subscribers identified on the signature pages hereto (each, a ?Subscriber? and collectively, the ?Subscribers?). Recitals Whereas, in June 2021, the Company commenced
July 21, 2021	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 15, 2021 Bionik Laboratories Corp.
July 19, 2021	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 14, 2021 Bionik Laboratories Corp.
July 19, 2021	EX-99.1	BIOIK Laboratories Announces Resignation of CEO, Names Interim CEO Exhibit 99.1 BIOIK Laboratories Announces Resignation of CEO, Names Interim CEO TORONTO & BOSTON-July 19, 2021-BIONIK Laboratories Corp. (OTCQB:BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today has announced that Chief Executive Officer and Board Member Dr. Eric Duss
June 24, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 18, 2021 Bionik Laboratories Corp.
June 24, 2021	EX-10.30	Stock Purchase Agreement, dated March 26, 2021 Exhibit 10.30 STOCK PURCHASE AGREEMENT THIS STOCK PURCHASE AGREEMENT (this ?Agreement?) is made as of the 26th day of March, 2021, by and between (a) Bionik Laboratories Corp., a Delaware corporation (the ?Company?), Bionik Inc., a Massachusetts corporation and a wholly-owned subsidiary of the Company (?US Sub?) and Bionik Laboratories Inc., a Canada corporation and a wholly-owned indirect subsidi
June 24, 2021	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the Fiscal Year Ended March 31, 2021 Or ? Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54717 Bionik Laboratori
June 24, 2021	EX-99.1	BIONIK Laboratories Corp. Condensed Consolidated Balance Sheets (Amounts expressed in US Dollars) Exhibit 99.1 June 24, 2021 BIONIK Laboratories Reports Fiscal 2021 Financial Results TORONTO & BOSTON - BIONIK Laboratories Corp. (OTCQB:BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today reported financial results for its fourth quarter and fiscal year 2021, for the
June 1, 2021	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report BIONIK LABORATORIES CORP. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report BIONIK LABORATORIES CORP. (Exact name of registrant as specified in its charter) Delaware 000-54717 27-1340346 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 483 Bay Street, N105 Toronto, Ontario M5G 2C9 (Address of
May 6, 2021	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 8-K 1 tm2115437d18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 30, 2021 Bionik Laboratories Corp. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-54717 27-1340346 (State or Other Jurisdicti
April 19, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 13, 2021 Bionik Laboratories Corp.
April 1, 2021	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 26, 2021 Bionik Laboratories Corp.
March 24, 2021	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 18, 2021 Bionik Laboratories Corp.
February 25, 2021	EX-10.1	Term Loan and Security Agreement dated February 12, 2021 (Incorporated by reference to the Company’s Current Report on Form 8-K, filed on February 25, 2021) Exhibit 10.1 TERM LOAN AND SECURITY AGREEMENT THIS TERM LOAN AND SECURITY AGREEMENT (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, this ?Agreement?) dated as of February 12, 2021 (the ?Closing Date?), is by and among Bionik Laboratories Corp., a Delaware corporation (the ?Borrower?), the lenders party hereto from time to time (each a ?Lender? and
February 25, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 8-K 1 tm218003d18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 24, 2021 Bionik Laboratories Corp. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-54717 27-1340346 (State or Other Jurisdic
February 11, 2021	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 for the Quarterly Period ended December 31, 2020 Or ¨ Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 for the transition period Commission File Number: 000-54717 Bionik Laborat
February 11, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 11, 2021 Bionik Laboratories Corp.
February 11, 2021	EX-99.1	BIONIK Laboratories Reports Fiscal 2021 Q3 Financial Results Revenues Increase 14% Over Same Period in Prior Year Exhibit 99.1 February 11, 2021 BIONIK Laboratories Reports Fiscal 2021 Q3 Financial Results Revenues Increase 14% Over Same Period in Prior Year TORONTO & BOSTON - BIONIK Laboratories Corp. (OTCQB:BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today reported financial r
December 18, 2020	EX-10.1	Allonge to Promissory Note, dated December 17, 2020 (Incorporated by reference to the Company’s Current Report on Form 8-K, filed on December 18, 2020) EX-10.1 2 tm2038858d1ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 ALLONGE TO PROMISSORY NOTE Allonge (this “Allonge”) to that certain Promissory Note (the “Promissory Note”) attached hereto as Exhibit 1 and made a part hereof in the principal amount of US$2,000,000.00, dated March 23, 2020, from Bionik Laboratories Corp., as obligor thereunder (“Maker”), to Celeste Management, as Holder (“Holder”). Capita
December 18, 2020	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 17, 2020 Bionik Laboratories Corp.
November 30, 2020	EX-10.1	Employment Agreement with Rich Russo Jr. (Incorporated by reference to the Company’s Current Report on Form 8-K, filed on November 30, 2020) Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT, is made as of the Start Date (as defined below), by and between BIONIK LABORATORIES CORP., a Delaware corporation (hereinafter referred to as the “Company”), and Richard Russo (hereinafter referred to as the “Employee”). RECITALS WHEREAS, the Company, directly or through its subsidiaries, is engaged in the business of medical device rese
November 30, 2020	EX-99.1	BIONIK Laboratories Corp. Appoints Rich Russo, Jr. as CFO Exhibit 99.1 BIONIK Laboratories Corp. Appoints Rich Russo, Jr. as CFO Rich Russo, Jr. brings substantial leadership and financial experience to BIONIK TORONTO & BOSTON - BIONIK Laboratories Corp. (OTCQB: BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced th
November 30, 2020	EX-10.2	Form of Subscription Agreement (incorporated by reference to the registrant’s Current Report on Form 8-K filed on July 21, 2021) Exhibit 10.2 Without Prejudice November 23, 2020 Leslie Markow 215 Glendonwynne Road Toronto, ON M6P 3G4 Revised – Supersedes letter dated November 19, 2020 Private & Confidential Dear Leslie, As discussed with you, we propose that your employment with Bionik Laboratories Inc. (the “Company”) will be terminated on January 29, 2021 (the “Termination Date”), and that beginning November 30, 2020 thro
November 30, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 24, 2020 Bionik Laboratories Corp.
November 12, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2020 Bionik Laboratories Corp.
November 12, 2020	EX-99.1	BIONIK Laboratories Announces Fiscal 2021 Q2 Financial Results Exhibit 99.1 BIONIK Laboratories Announces Fiscal 2021 Q2 Financial Results TORONTO & BOSTON – November 12, 2020 – BIONIK Laboratories Corp. (OTCQB: BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for its second quarter of fiscal year 20
November 12, 2020	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 for the Quarterly Period ended September 30, 2020 Or ¨ Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 for the transition period Commission File Number: 000-54717 Bionik Labora
October 8, 2020	EX-3.1	Certificate of Amendment to Amended and Restated Certificate Of Incorporation, as amended, dated October 6, 2020 (incorporated by reference to the Company’s Current Report on Form 8-K, filed on October 8, 2020) Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE CERTIFICATE OF INCORPORATION OF BIONIK LABORATORIES CORP. Bionik Laboratories Corp. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows: 1. The name of the Corporation is Bionik Laboratories Corp. and the Corpor
October 8, 2020	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 6, 2020 Bionik Laboratories Corp.
October 5, 2020	8-K	Submission of Matters to a Vote of Security Holders - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 5, 2020 Bionik Laboratories Corp.
September 30, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 30, 2020 Bionik Laboratories Corp.
September 30, 2020	EX-99.1	BIONIK Laboratories Announces Sale of New InMotion® ARM/HAND Robotic Device to VA Rehabilitation Research & Development’s Center for Neurorestoration and Neurotechnology VA-funded center purchases second InMotion® ARM/HAND interactive therapy system Exhibit 99.1 BIONIK Laboratories Announces Sale of New InMotion® ARM/HAND Robotic Device to VA Rehabilitation Research & Development’s Center for Neurorestoration and Neurotechnology VA-funded center purchases second InMotion® ARM/HAND interactive therapy system to test new approaches for restoring physical function of veterans with neurologic disease or injury TORONTO and BOSTON – September 30, 2
September 8, 2020	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
August 27, 2020	PRE 14A	- PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin
August 13, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 tm2027465d18k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 13, 2020 Bionik Laboratories Corp. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-54717 27-1340346 (State or Other Jurisdict
August 13, 2020	EX-99.1	BIONIK Laboratories Announces Fiscal 2021 Q1 Financial Results EX-99.1 2 tm2027465d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 BIONIK Laboratories Announces Fiscal 2021 Q1 Financial Results TORONTO & BOSTON – August 13, 2020 - BIONIK Laboratories Corp. (OTCQB:BNKL) ("BIONIK"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced finan
August 12, 2020	10-Q	Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 for the Quarterly Period ended June 30, 2020 Or ¨ Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 for the transition period Commission File Number: 000-54717 Bionik Laboratorie
July 8, 2020	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 6, 2020 Bionik Laboratories Corp.
June 30, 2020	EX-4.6	Description of the Company’s Securities (incorporated by reference to the Company’s Annual Report on Form 10-K for the Fiscal Year ended March 31, 2020, filed with the Commission on June 29, 2020) EX-4.6 2 tm2015431d1ex4-6.htm EXHIBIT 4.6 Exhibit 4.6 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the common stock of Bionik Laboratories Corp. (referred to as “the Company”, “we”, “us” and “our” unless specified otherwise) is based upon relevant provisions of the Company’s Amended and Restated Cer
June 30, 2020	EX-10.18	Amendment No. 1 to Eric Dusseux Employment Agreement (Incorporated by reference to the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2020, filed on June 29, 2020) Exhibit 10.18 Amendment #1 to Employment Agreement (September 1, 2017) between Eric Dusseux [“Dr. Dusseux”] and Bionik Laboratories Corp. and Bionik Laboratories Inc. [“Bionik”] This Amendment #1 is to record changes to the following sections of the Employment Agreement: Section 1.2 Reporting and Duties Original: “The majority of time is to spent at Bionik’s offices in Toronto currently located at
June 30, 2020	EX-99.1	BIONIK Laboratories Announces Fiscal 2020 Financial Results Exhibit 99.1 BIONIK Laboratories Announces Fiscal 2020 Financial Results TORONTO & BOSTON – June 30, 2020 - BIONIK Laboratories Corp. (OTCQB:BNKL) ("BIONIK"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the fiscal year ended March 31, 2
June 30, 2020	10-K	Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the Fiscal Year Ended March 31, 2020 Or ¨ Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-54717 Bionik Laboratori
June 30, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 30, 2020 Bionik Laboratories Corp.
June 30, 2020	EX-10.8	Amendment No. 1 to Leslie Markow’s Employment Agreement Exhibit 10.8 BIONIK LABORATORIES CORP. July 30, 2015 Leslie Markow Dear Leslie, Bionik Laboratories is pleased to present you with an Offer of Employment for the position of CFO reporting to the CEO, Peter Bloch, commencing August 4, 2015. This appointment is subject to the approval of the Board on August 11, 2015. It is understood that you will be giving TMF Group your resignation during the week
June 25, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 25, 2020 Bionik Laboratories Corp.
June 25, 2020	EX-99.1	BIONIK Laboratories Launches InMotion Connect™, Driving Outcomes through Internet of Things (IoT) and Intelligent Data InMotion Connect™, a cloud-based data analytics solution, combines real-time robot data with deep expertise of BIONIK’s clinical sp Exhibit 99.1 BIONIK Laboratories Launches InMotion Connect™, Driving Outcomes through Internet of Things (IoT) and Intelligent Data InMotion Connect™, a cloud-based data analytics solution, combines real-time robot data with deep expertise of BIONIK’s clinical specialists to partner with each clinic, promoting robot utilization, supporting clinician engagement, and enhancing patient care BIONIK pa
June 9, 2020	EX-10.1	Form of Subscription Agreement (Incorporated by reference to the Company’s Current Report on Form 8-K, filed on June 9, 2020) Exhibit 10.1 SUBSCRIPTION AGREEMENT This Subscription Agreement (this “Agreement”) is made as of the date set forth on the signature page hereto, by and among Bionik Laboratories Corp., a Delaware corporation (the “Company”), and the subscribers identified on the signature pages hereto (each, a “Subscriber” and collectively, the “Subscribers”). Recitals Whereas, in September 2019, the Company comm
June 9, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 3, 2020 Bionik Laboratories Corp.
June 9, 2020	EX-10.2	Form of Promissory Note (Incorporated by reference to the Company’s Current Report on Form 8-K, filed on June 9, 2020) Exhibit 10.2 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM, THE REQUIREMENTS OF SUCH ACT OR SUCH LAWS. BIONIK LABORATORIES CORP. SECURED CONVERTIBLE P
June 9, 2020	EX-10.3	Allonge to Convertible Promissory Note dated June 3, 2020 (Incorporated by reference to the Company’s Current Report on Form 8-K, filed on June 9, 2020) Exhibit 10.3 ALLONGE #2 TO CONVERTIBLE PROMISSORY NOTE Allonge #2 (this “Allonge”) to that certain Convertible Promissory Note dated September 26, 2019, as amended by that Allonge #1 dated as of March 30, 2020 (as so amended, the “Convertible Promissory Note”) attached hereto as Exhibit 1 and made a part hereof in the principal amount of $70,000, from Bionik Laboratories Corp., as Maker (“Maker”),
June 1, 2020	SD	- FORM SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report BIONIK LABORATORIES CORP. (Exact name of registrant as specified in its charter) Delaware 000-54717 27-1340346 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 483 Bay Street, N105 Toronto, Ontario M5G 2C9 (Address of
May 22, 2020	8-K	Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 18, 2020 Bionik Laboratories Corp.
May 12, 2020	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 6, 2020 Bionik Laboratories Corp.
May 12, 2020	EX-10.1	Promissory Note, dated May 1, 2020 Exhibit 10.1 Date Loan Amount Interest Rate after Deferment Period Deferment Period 05/01/2020 $459,912.00 1.00% fixed per annum 6 months This Promissory Note (“Note”) sets forth and confirms the terms and conditions of a term loan to BIONIK, INC. (whether one or more than one, “Borrower”) from Bank of America, NA, a national banking association having an address of P.O. Box 15220, Wilmington, DE
March 27, 2020	EX-10.1	Promissory Note dated March 23, 2020 (Incorporated by reference to the Company’s Current Report on Form 8-K, filed on March 27, 2020) Exhibit 10.1 BIONIK LABORATORIES CORP. PROMISSORY NOTE Principal Amount: US$2,000,000.00 Issue Date: March 23, 2020 Bionik Laboratories Corp., a Delaware corporation (the “Company”), for value received, hereby promises to pay to Celeste Management (the “Holder”), the principal amount of Two Million Dollars (US$2,000,000.00) (the “Principal Amount”), without demand, on the Maturity Date (as hereina
March 27, 2020	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 23, 2020 Bionik Laboratories Corp.
March 27, 2020	EX-10.2	Allonge to Convertible Promissory Note dated March 27, 2020 (Incorporated by reference to the Company’s Current Report on Form 8-K, filed on March 27, 2020) Exhibit 10.2 ALLONGE #1 TO CONVERTIBLE PROMISSORY NOTE Allonge #1 (this “Allonge”) to that certain Convertible Promissory Note (the “Convertible Promissory Note”) attached hereto as Exhibit 1 and made a part hereof in the principal amount of $70,000 dated September 26, 2019 from Bionik Laboratories Corp., as Maker (“Maker”), to Celeste Management, as Holder (“Holder”). Maker and Holder agree that
February 21, 2020	424B3	BIONIK LABORATORIES CORP. 156,250 Shares of Common Stock Filed pursuant to 424(b)(3) Registration No. 333-233796 PROSPECTUS SUPPLEMENT (To Prospectus dated November 12, 2019) BIONIK LABORATORIES CORP. 156,250 Shares of Common Stock This prospectus supplement (the “Prospectus Supplement”) supplements our prospectus dated November 12, 2019 (the “Prospectus”), relating to the offer and sale from time to time of up to 156,250 shares of our common stock issu
February 14, 2020	10-Q	BNKL / Bionik Laboratories Corp. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the Quarterly Period ended December 31, 2019 or ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the transition period from to Commission File Number: 000-54717 Bionik
February 14, 2020	EX-99.1	BIONIK Laboratories Announces Third Quarter Fiscal 2020 Financial Results Exhibit 99.1 BIONIK Laboratories Announces Third Quarter Fiscal 2020 Financial Results TORONTO & BOSTON—February 14, 2020- BIONIK Laboratories Corp. (OTCQB: BNKL) ("BIONIK" or the "Company"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for
February 14, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 14, 2020 Bionik Laboratories Corp.
February 13, 2020	SC 13G	BNKL / Bionik Laboratories Corp. / Lombard International Assurance S.a. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Bionik Laboratories Corp (Name of Issuer) Common stock, par value $0.001 per Share (Title of Class of Securities) 09074A208 (CUSIP Number) 28 March 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic
January 30, 2020	EX-99.1	BIONIK Laboratories Announces Regulatory Approval and First Sale of its InMotion® ARM Robotic Technology by its Exclusive Distributor in South Korea Distributor Curexo secures first purchase from SeoSong Rehabilitation Hospital just days after securi Exhibit 99.1 BIONIK Laboratories Announces Regulatory Approval and First Sale of its InMotion® ARM Robotic Technology by its Exclusive Distributor in South Korea Distributor Curexo secures first purchase from SeoSong Rehabilitation Hospital just days after securing device clearance from the South Korean Ministry of Food and Drug Safety TORONTO, BOSTON – January 30, 2020 - BIONIK Laboratories Corp.
January 30, 2020	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 30, 2020 Bionik Laboratories Corp.
January 28, 2020	EX-10.1	Distribution Agreement (Incorporated by reference to the Company’s Current Report on Form 8-K, filed on, January 28, 2020) Exhibit 10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) would likely cause competitive harm to the Company, if publicly disclosed. Double asterisks surrounded by brackets denote omissions. Final Execution Copy Confidential Distribution Agreement This Distribution Agreement (“This “Agreement”), made and entered into as of the 13th
January 28, 2020	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders, Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 22, 2020 Bionik Laboratories Corp.
December 19, 2019	DEF 14A	BNKL / Bionik Laboratories Corp. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
November 18, 2019	424B3	BIONIK LABORATORIES CORP. 156,250 Shares of Common Stock Filed pursuant to 424(b)(3) Registration No. 333-233796 PROSPECTUS SUPPLEMENT (To Prospectus dated November 12, 2019) BIONIK LABORATORIES CORP. 156,250 Shares of Common Stock This prospectus supplement (the “Prospectus Supplement”) supplements our prospectus dated November 12, 2019 (the “Prospectus”), relating to the offer and sale from time to time of up to 156,250 shares of our common stock issu
November 15, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 15, 2019 Bionik Laboratories Corp.
November 15, 2019	EX-99.1	BIONIK Laboratories Announces Second Quarter Fiscal 2020 Financial Results Exhibit 99.1 BIONIK Laboratories Announces Second Quarter Fiscal 2020 Financial Results TORONTO and BOSTON (November 15, 2019) – BIONIK Laboratories Corp. (OTCQB: BNKL) ("BIONIK" or the "Company"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial result
November 14, 2019	EX-10.2	Equity Compensation Agreement, dated October 15, 2019, with Eric Dusseux (Incorporated by reference to the Company’s Quarterly Report on Form 10-Q, filed on November 14, 2019) Exhibit 10.2 EQUITY COMPENSATION AGREEMENT EQUITY COMPENSATION AGREEMENT (this "Agreement"), dated October 15, 2019 but effective as of the 26th day of July, 2019 (the “Grant Date”), between BIONlK LABORATORIES CORP., a corporation incorporated under the laws of the state of Delaware (hereinafter referred to as the "Issuer”), and Eric Dusseux (hereinafter referred to as the "Recipient"; the Issuer
November 14, 2019	10-Q	BNKL / Bionik Laboratories Corp. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 for the Quarterly Period ended September 30, 2019 Or ¨ Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 for the transition period Commission File Number: 000-54717 Bionik Labora
November 14, 2019	EX-10.1	Form of Equity Compensation Agreement – Non-Management Director (Incorporated by reference to the Company’s Quarterly Report on Form 10-Q, filed on November 14, 2019) Exhibit 10.1 EQUITY COMPENSATION AGREEMENT EQUITY COMPENSATION AGREEMENT (this “Agreement”), dated October 29, 2019 but effective as of the 26th day of July 2019 (the “Grant Date”), between BIONlK LABORATORIES CORP., a corporation incorporated under the laws of the state of Delaware (hereinafter referred to as the “Issuer”) and [] (hereinafter referred to as the “Recipient”, the Issuer and the Rec
November 12, 2019	S-1/A	BNKL / Bionik Laboratories Corp. S-1/A - - FORM S-1/A As filed with the Securities and Exchange Commission on November 12, 2019 Registration No.
November 12, 2019	CORRESP	BNKL / Bionik Laboratories Corp. CORRESP - - November 12, 2019 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F.
November 5, 2019	CORRESP	BNKL / Bionik Laboratories Corp. CORRESP - - November 5, 2019 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Washington, D.
October 28, 2019	SC 13D/A	BNKL / Bionik Laboratories Corp. / Gaston-dreyfus Remi - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Bionik Laboratories Corp. (Name of Issuer) Common Stock, par value $0.001 per Share (Title of Class of Securities) 09074A109 (CUSIP Number) Remi Gaston-Dreyfus 46 rue Pierre Charron F-75008 Paris, France +33(0)153931212 (Name, Address and Telephone Numbe
October 15, 2019	EX-99.1	BIONIK Laboratories Partners with Intelliware Development to Provide Seamless Connectivity Between InMotionTM Robotic Devices and Hospital Information Systems Companies collaborate to produce customized dynamic data management platform to empower sup Exhibit 99.1 BIONIK Laboratories Partners with Intelliware Development to Provide Seamless Connectivity Between InMotionTM Robotic Devices and Hospital Information Systems Companies collaborate to produce customized dynamic data management platform to empower superior patient outcomes and increased asset productivity TORONTO & BOSTON – October 14, 2019 - BIONIK Laboratories Corp. (OTCQB:BNKL) ("BI
October 15, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 14, 2019 Bionik Laboratories Corp.
October 11, 2019	S-1/A	BNKL / Bionik Laboratories Corp. S-1/A - - FORM S-1/A As filed with the Securities and Exchange Commission on October 11, 2019 Registration No.
October 11, 2019	CORRESP	BNKL / Bionik Laboratories Corp. CORRESP - - October 11, 2019 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Washington, D.
September 30, 2019	EX-10.1	Allonge to Promissory Note (Incorporated by reference to the Company’s Current Report on Form 8-K, filed on September 30, 2019) Exhibit 10.1 ALLONGE TO PROMISSORY NOTE Allonge (this “Allonge”) to that certain Promissory Note (the “Promissory Note”) attached hereto as Exhibit 1 and made a part hereof in the principal amount of (a) US$500,000.00, dated May 8, 2019, from Bionik Laboratories Corp., as obligor (“Maker”), to Star SCI, as Holder (“Holder”). Maker and Holder agree that the Promissory Note shall be revised as follo
September 30, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 24, 2019 Bionik Laboratories Corp.
September 16, 2019	S-1	BNKL / Bionik Laboratories Corp. S-1 - Registration Statement - FORM S-1 S-1 1 tv527766s-1.htm FORM S-1 As filed with the Securities and Exchange Commission on September 16, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BIONIK LABORATORIES CORP. (Exact name of Registrant as specified in its charter) Delaware 3842 27-1340346 (State or Other Jurisdiction
September 4, 2019	EX-10.1	Employment Agreement of Loren Wass, dated as of September 3, 2019 (Incorporated by reference to the Company’s Current Report on Form 8-K, filed on September 4, 2019) Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT, is made as of the Start Date (as defined below), by and between BIONIK LABORATORIES CORP., a Delaware corporation (hereinafter referred to as the “Company”), and Loren Wass (hereinafter referred to as the “Employee”). RECITALS WHEREAS, the Company, directly or through its subsidiaries, is engaged in the business of medical device researc
September 4, 2019	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 3, 2019 Bionik Laboratories Corp.
September 4, 2019	EX-99.1	Industry veteran brings extensive experience driving the commercialization of robotic technologies within healthcare Exhibit 99.1 BIONIK Laboratories Appoints Loren Wass as Chief Commercial Officer Industry veteran brings extensive experience driving the commercialization of robotic technologies within healthcare TORONTO & BOSTON – September 4, 2019 - BIONIK Laboratories Corp. (OTCQB:BNKL) ("BIONIK" or the "Company"), a robotics company focused on providing rehabilitation and assistive technology solutions to in
August 28, 2019	SC 13D/A	BNKL / Bionik Laboratories Corp. / Gaston-dreyfus Remi - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Bionik Laboratories Corp. (Name of Issuer) Common Stock, par value $0.001 per Share (Title of Class of Securities) 09074A109 (CUSIP Number) Remi Gaston-Dreyfus 46 rue Pierre Charron F-75008 Paris, France +33(0)153931212 (Name, Address and Telephone Numbe
August 13, 2019	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 13, 2019 Bionik Laboratories Corp.
August 13, 2019	EX-99.1	BIONIK Laboratories’ Fiscal Year 2020 Q1 Financial Results Feature 57% Increase in Sales Exhibit 99.1 BIONIK Laboratories’ Fiscal Year 2020 Q1 Financial Results Feature 57% Increase in Sales TORONTO & BOSTON – August 13, 2019 - BIONIK Laboratories Corp. (OTCQB:BNKL) ("BIONIK" or the "Company"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, yesterday announced fin
August 12, 2019	10-Q	BNKL / Bionik Laboratories Corp. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x Quarterly Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 for the Quarterly Period ended June 30, 2019 Or ¨ Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 for the transition period Commission File Number: 000-54717 Bionik Laboratorie
August 7, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 1, 2019 Bionik Laboratories Corp.
July 31, 2019	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sales of Equity Securities, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 25, 2019 Bionik Laboratories Corp.
July 19, 2019	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 17, 2019 Bionik Laboratories Corp.
July 17, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant 8-K 1 tv5253088k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 12, 2019 Bionik Laboratories Corp. (Exact Name of Registrant as Specified in Its Charter) Delaware 000-54717 27-1340346 (State or Other Jurisdiction o
July 12, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 8, 2019 Bionik Laboratories Corp.
July 2, 2019	EX-99.1	BIONIK Laboratories’ Fiscal 2019 Financial Results Feature 229% Increase in Sales Exhibit 99.1 BIONIK Laboratories’ Fiscal 2019 Financial Results Feature 229% Increase in Sales TORONTO & BOSTON – July 2, 2019 - BIONIK Laboratories Corp. (OTCQB:BNKL) ("BIONIK" or the "Company"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, yesterday announced financial res
July 2, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 27, 2019 Bionik Laboratories Corp.
July 1, 2019	10-K	BNKL / Bionik Laboratories Corp. 10-K - Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x Annual Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the Fiscal Year Ended March 31, 2019 Or ¨ Transition Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 For the transition period fromto Commission File Number: 000-54717 Bionik Laboratorie
June 24, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 18, 2019 Bionik Laboratories Corp.
June 17, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 11, 2019 Bionik Laboratories Corp.
June 17, 2019	EX-10.2	Form of Promissory Note (Incorporated by reference to the Company’s Current Report on Form 8-K, filed on June 17, 2019) Exhibit 10.2 THIS NOTE HAS NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR UNDER THE SECURITIES LAWS OF ANY STATE OR OTHER JURISDICTION, AND MAY NOT BE SOLD, ASSIGNED, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT IN COMPLIANCE WITH, OR PURSUANT TO AN EXEMPTION FROM, THE REQUIREMENTS OF SUCH ACT OR SUCH LAWS. BIONIK LABORATORIES CORP. SECURED CONVERTIBLE P
June 17, 2019	EX-10.1	Form of Subscription Agreement (Incorporated by reference to the Company’s Current Report on Form 8-K, filed on June 17, 2019) Exhibit 10.1 SUBSCRIPTION AGREEMENT This Subscription Agreement (this “Agreement”) is made as of the date set forth on the signature page hereto, by and among Bionik Laboratories Corp., a Delaware corporation (the “Company”), and the subscribers identified on the signature pages hereto (each, a “Subscriber” and collectively, the “Subscribers”). Recitals Whereas, the Company seeks to sell from time
May 31, 2019	SD	BNKL / Bionik Laboratories Corp. SD - - SPECIALIZED DISCLOSURE REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report BIONIK LABORATORIES CORP. (Exact name of registrant as specified in its charter) Delaware 000-54717 27-1340346 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 483 Bay Street, N105 Toronto, Ontario M5G 2C9 (Address of
May 28, 2019	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 28, 2019 Bionik Laboratories Corp.
May 28, 2019	EX-99.1	Landmark RATULS Research Trial of Robot-Assisted Stroke Therapy Utilizes BIONIK’s InMotion Robotic Therapy Systems Outcomes of trial, funded by The National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Program, presented at Exhibit 99.1 Landmark RATULS Research Trial of Robot-Assisted Stroke Therapy Utilizes BIONIK’s InMotion Robotic Therapy Systems Outcomes of trial, funded by The National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Program, presented at 5th European Stroke Organisation Conference (ESOC) in Milan TORONTO and BOSTON (May 28, 2019) – BIONIK Laboratories Corp. (OTCQB: BNKL)
May 21, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 15, 2019 Bionik Laboratories Corp.
May 17, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2019 Bionik Laboratories Corp.
May 16, 2019	SC 13D/A	BNKL / Bionik Laboratories Corp. / Gaston-dreyfus Remi - SC 13D/A Activist Investment SC 13D/A 1 tv521613sc13d-a.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Bionik Laboratories Corp. (Name of Issuer) Common Stock, par value $0.001 per Share (Title of Class of Securities) 09074A109 (CUSIP Number) Remi Gaston-Dreyfus 46 rue Pierre Charron F-75008 Paris, France +33(0)1539
May 10, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2019 Bionik Laboratories Corp.
May 10, 2019	EX-10.1	Promissory Note, dated as of May 8, 2019 (Incorporated by reference to the Company’s Current Report on Form 8-K, filed on May 10, 2019) Exhibit 10.1 BIONIK LABORATORIES CORP. PROMISSORY NOTE Principal Amount: US$500,000.00 Issue Date: May 8, 2019 Bionik Laboratories Corp., a Delaware corporation (the “Company”), for value received, hereby promises to pay to Star SCI or its permitted assigns or successors (the “Holder”), the principal amount of Five Hundred Thousand Dollars (US$500,000.00) (the “Principal Amount”), without demand,
April 10, 2019	SC 13D/A	BNKL / Bionik Laboratories Corp. / Auberton-herve Andre-jacques - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Bionik Laboratories Corp. (Name of Issuer) Common Stock, par value $0.001 per Share (Title of Class of Securities) 09074A109 (CUSIP Number) Andre-Jacques Auberton-Herve 18 Chemin de la Vierge Noire La Tronche, France 38700 33686567758 (Name, Address and
April 2, 2019	8-K	Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 28, 2019 Bionik Laboratories Corp.
March 19, 2019	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 18, 2019 Bionik Laboratories Corp.
March 15, 2019	RW	BNKL / Bionik Laboratories Corp. RW March 15, 2019 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F.
February 25, 2019	S-1/A	BNKL / Bionik Laboratories Corp. FORM S-1/A As filed with the Securities and Exchange Commission on February 25, 2019 Registration No.
February 15, 2019	424B3	BIONIK LABORATORIES CORP. 479,535 Shares of Common Stock Filed pursuant to 424(b)(3) Registration No. 333-222236 PROSPECTUS SUPPLEMENT (To Prospectus dated October 24, 2018) BIONIK LABORATORIES CORP. 479,535 Shares of Common Stock This prospectus supplement (the “Prospectus Supplement”) supplements our prospectus dated October 24, 2018, as supplemented by the Prospectus Supplement dated November 26, 2018 (collectively, the “Prospectus”), relating to the
February 15, 2019	424B3	BIONIK LABORATORIES CORP. 251,303 Shares of Common Stock Filed pursuant to 424(b)(3) Registration No. 333-222236 PROSPECTUS SUPPLEMENT (To Prospectus dated October 24, 2018) BIONIK LABORATORIES CORP. 251,303 Shares of Common Stock This prospectus supplement (the “Prospectus Supplement”) supplements our prospectus dated October 24, 2018, as supplemented by the Prospectus Supplement dated November 26, 2018 (collectively, the “Prospectus”), relating to the
February 15, 2019	EX-4.7	Form of Warrant Agent Agreement by and between the Company and VStock Transfer, LLC and Form of Warrant Certificate for Registered Offering Exhibit 4.7 WARRANT AGENT AGREEMENT WARRANT AGENT AGREEMENT (this “Warrant Agreement”) dated as of February [·], 2019 (the “Issuance Date”) between Bionik Laboratories Corp., a company incorporated under the laws of the State of Delaware (the “Company”), and [·] (the “Warrant Agent”). WHEREAS, pursuant to the terms of that certain Underwriting Agreement (“Underwriting Agreement”), dated February [
February 15, 2019	S-1/A	BNKL / Bionik Laboratories Corp. S-1/A As filed with the Securities and Exchange Commission on February 15, 2019 Registration No.
February 14, 2019	S-1/A	BNKL / Bionik Laboratories Corp. S-1/A As filed with the Securities and Exchange Commission on February 14, 2019 Registration No.
February 14, 2019	EX-1.1	Form of Underwriting Agreement Exhibit 1.1 UNDERWRITING AGREEMENT [●], 2019 ThinkEquity, a division of Fordham Financial Management, Inc. WestPark Capital, Inc. As Representatives of the Underwriters named on Schedule 1 attached hereto c/o ThinkEquity, a division of Fordham Financial Management, Inc. 17 State Street, 22nd Floor New York, NY 10004 c/o WestPark Capital, Inc. 1900 Avenue of the Stars, Suite 310 Los Angeles, CA 900
February 14, 2019	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 13, 2019 Bionik Laboratories Corp.
February 14, 2019	EX-10.1	Form of Allonge to Bridge Notes (Incorporated by reference to the Company’s Current Report on Form 8-K, filed on February 14, 2019) Exhibit 10.1 ALLONGE TO CONVERTIBLE PROMISSORY NOTES Allonge (this “Allonge”) to those certain Convertible Promissory Notes (the “Convertible Notes”) referenced hereto in Exhibit 1 and made a part hereof, in each case from Bionik Laboratories Corp. (“Borrower”), to the Holders described therein (the “Holders”). Capitalized terms used herein but not otherwise defined shall have the meanings ascribe
February 14, 2019	EX-10.2	Form of Allonge to Short-Term Convertible Promissory Notes (Incorporated by reference to the Company’s Current Report on Form 8-K, filed on February 14, 2019) Exhibit 10.2 ALLONGE TO CONVERTIBLE PROMISSORY NOTES Allonge (this “Allonge”) to those certain Convertible Promissory Notes (the “Convertible Notes”) referenced hereto in Exhibit 1 and made a part hereof, in each case from Bionik Laboratories Corp. (“Borrower”), to the Holders described therein (the “Holders”). Capitalized terms used herein but not otherwise defined shall have the meanings ascribe
February 13, 2019	SC 13G	BNKL / Bionik Laboratories Corp. / Lombard International Assurance S.a. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Bionik Laboratories Corp (Name of Issuer) Common stock, par value $0.001 per Share (Title of Class of Securities) 09074A208 (CUSIP Number) March 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whi
February 11, 2019	DEF 14A	BNKL / Bionik Laboratories Corp. DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin
February 11, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 11, 2019 Bionik Laboratories Corp.
February 11, 2019	EX-99.1	BIONIK Laboratories Third Quarter Fiscal 2019 Financial Results Feature 256% Increase in Sales Exhibit 99.1 BIONIK Laboratories Third Quarter Fiscal 2019 Financial Results Feature 256% Increase in Sales TORONTO and BOSTON (February 11, 2019) – BIONIK Laboratories Corp. (OTCQB: BNKL) ("BIONIK" or the "Company"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announ
February 11, 2019	10-Q	BNKL / Bionik Laboratories Corp. FORM 10-Q (Quarterly Report) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended December 31, 2018 -OR- ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities And Exchange Act of 1934 for the transition period fromto Commission File Number: 000-54717 BIONIK LABORATORIES CORP.
February 11, 2019	DEL AM	BNKL / Bionik Laboratories Corp. DEL AM February 11, 2019 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F.
January 24, 2019	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 22, 2019 Bionik Laboratories Corp.
January 23, 2019	EX-4.6	Form of Representative’s Warrant Exhibit 4.6 EXHIBIT A Form of Representative’s Warrant Agreement THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HU
January 23, 2019	EX-1.1	Form of Underwriting Agreement Exhibit 1.1 UNDERWRITING AGREEMENT [●], 2019 WestPark Capital, Inc. As Representative of the Underwriters named on Schedule 1 attached hereto 1900 Avenue of the Stars, Suite 310 Los Angeles, CA 90067 Ladies and Gentlemen: The undersigned, Bionik Laboratories Corp. (the “Company”), hereby confirms its agreement (this “Agreement”) with WestPark Capital, Inc. (the “Representative”) and with the other
January 23, 2019	S-1/A	BNKL / Bionik Laboratories Corp. S-1/A As filed with the Securities and Exchange Commission on January 23, 2019 Registration No.
January 23, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 23, 2019 Bionik Laboratories Corp.
January 23, 2019	EX-99.1	BIONIK Laboratories Launches Next-Generation InMotion ARM/HAND Robotic System to Improve Rehabilitation for Stroke Survivors Exhibit 99.1 BIONIK Laboratories Launches Next-Generation InMotion ARM/HAND Robotic System to Improve Rehabilitation for Stroke Survivors Company introduces new technology at the American Physical Therapy Association Combined Sections Meeting January 23-26 in Washington, D.C. TORONTO and BOSTON (January 23, 2019) – BIONIK Laboratories Corp. (OTCQB: BNKL) (“BIONIK” or the "Company"), a pioneering h
January 8, 2019	S-1/A	BNKL / Bionik Laboratories Corp. S-1/A As filed with the Securities and Exchange Commission on January 7, 2019 Registration No.
January 5, 2019	EX-99.1	REHABILITATION THERAPY AND MOBILITY SOLUTIONS 2019 Ticker: BNKL Exhibit 99.1 REHABILITATION THERAPY AND MOBILITY SOLUTIONS 2019 Ticker: BNKL This document is private and confidential, contains sensitive business information of Bionik Laboratories Corp . (“ Bionik ”) and is not for public distribution . This document has been prepared for informational purposes only and is provided personally to you . By accepting this document you agree to keep its contents st
January 5, 2019	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 4, 2019 Bionik Laboratories Corp.
December 31, 2018	S-1/A	BNKL / Bionik Laboratories Corp. S-1/A As filed with the Securities and Exchange Commission on December 31, 2018 Registration No.
December 19, 2018	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 18, 2018 Bionik Laboratories Corp.
December 17, 2018	EX-10.1	Sale of Goods Agreement, dated as of December 13, 2018, by and between Bionik Inc. and CHC Management Services, LLC (Incorporated by reference to the Company’s Current Report on Form 8-K, filed on December 17, 2018) Exhibit 10.1 SALE OF GOODS AGREEMENT This SALE OF GOODS AGREEMENT (this “Agreement”), dated as of December 13, 2018, is entered into by and between Bionik Inc., a Massachusetts corporation (“Seller”), and CHC Management Services, LLC, a Missouri Limited Liability Company on behalf of the Facilities set forth on Exhibit A (“Buyer”, and together with Seller, the “Parties”, and sometimes each, a “Par
December 17, 2018	8-K	Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): December 14, 2018 Bionik Laboratories Corp.
December 17, 2018	EX-99.1	BIONIK Laboratories Announces Multi-Year Purchase Agreement and Ongoing Relationship with Kindred Hospital Rehabilitation Services for InMotion Arm™ Robotic Systems Multi-year commitment will place InMotion Arm™ Robots in existing and future Kindred Exhibit 99.1 BIONIK Laboratories Announces Multi-Year Purchase Agreement and Ongoing Relationship with Kindred Hospital Rehabilitation Services for InMotion Arm™ Robotic Systems Multi-year commitment will place InMotion Arm™ Robots in existing and future Kindred Inpatient Rehabilitation Hospitals across the United States TORONTO and BOSTON (December 17, 2018) – BIONIK Laboratories Corp. (OTCQB: BN
November 26, 2018	424B3	BIONIK LABORATORIES CORP. 251,303 Shares of Common Stock Filed pursuant to 424(b)(3) Registration No. 333-222236 PROSPECTUS SUPPLEMENT (To Prospectus dated October 24, 2018) BIONIK LABORATORIES CORP. 251,303 Shares of Common Stock This prospectus supplement (the “Prospectus Supplement”) supplements our prospectus dated October 24, 2018 (the “Prospectus”), relating to the offer and sale from time to time of up to approximately 251,303 shares of our commo
November 26, 2018	424B3	BIONIK LABORATORIES CORP. 479,535 Shares of Common Stock Filed pursuant to 424(b)(3) Registration No. 333-222236 PROSPECTUS SUPPLEMENT (To Prospectus dated October 24, 2018) BIONIK LABORATORIES CORP. 479,535 Shares of Common Stock This prospectus supplement (the “Prospectus Supplement”) supplements our prospectus dated October 24, 2018 (the “Prospectus”), relating to the offer and sale from time to time of up to: · Approximately 218,777 shares of our co
November 19, 2018	S-1/A	BNKL / Bionik Laboratories Corp. S-1/A As filed with the Securities and Exchange Commission on November 19, 2018 Registration No.
November 13, 2018	EX-99.1	BIONIK Laboratories Second Quarter Fiscal 2019 Financial Results Feature 147% Increase in Revenues Exhibit 99.1 BIONIK Laboratories Second Quarter Fiscal 2019 Financial Results Feature 147% Increase in Revenues TORONTO and BOSTON (November 13, 2018) – BIONIK Laboratories Corp. (OTCQB: BNKLD) ("BIONIK" or the "Company"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today a
November 13, 2018	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 13, 2018 Bionik Laboratories Corp.
November 13, 2018	10-Q	BNKL / Bionik Laboratories Corp. FORM 10-Q (Quarterly Report) SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period ended September 30, 2018 -OR- o Transition Report Pursuant to Section 13 or 15(d) of the Securities And Exchange Act of 1934 for the transition period fromto Commission File Number: 000-54717 BIONIK LABORATORIES CORP.
November 6, 2018	8-K	Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 31, 2018 Bionik Laboratories Corp.
October 30, 2018	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 30, 2018 Bionik Laboratories Corp.
October 30, 2018	EX-99.1	# # # Exhibit 99.1 Bionik Laboratories Files Registration Statement for Proposed Follow-On Offering TORONTO and BOSTON (October 30, 2018) – Bionik Laboratories Corp. (OTCQB: BNKL) (“Bionik” or the "Company"), a pioneering healthcare company combining artificial intelligence and innovative robotics technology to help individuals from hospital to home to regain mobility, announced today the filing of a re
October 29, 2018	S-1	BNKL / Bionik Laboratories Corp. S-1 As filed with the Securities and Exchange Commission on October 29, 2018 Registration No.
October 29, 2018	EX-99.1	# # # Exhibit 99.1 Bionik Laboratories Announces 1-for-150 Reverse Stock Split TORONTO and BOSTON (October 29, 2018) – Bionik Laboratories Corp. (OTCQB: BNKL) (“Bionik” or the "Company"), a pioneering healthcare company combining artificial intelligence and innovative robotics technology to help individuals from hospital to home to regain mobility, announced today that its board of directors has establi
October 29, 2018	EX-3.1	Certificate of Amendment of the Certificate of Incorporation, dated October 26, 2018 (incorporated by reference to the Company’s Current Report on Form 8-K filed on October 29, 2018). Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE CERTIFICATE OF INCORPORATION OF BIONIK LABORATORIES CORP. Bionik Laboratories Corp. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows: 1. The name of the Corporation is Bionik Laboratories Corp. and the Corpor
October 29, 2018	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 26, 2018 Bionik Laboratories Corp.
October 24, 2018	424B3	BIONIK LABORATORIES CORP. 71,930,025 Shares of Common Stock 424B3 1 tv505441424b3.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-222236 PROSPECTUS BIONIK LABORATORIES CORP. 71,930,025 Shares of Common Stock This prospectus relates to the offer and sale from time to time of up to: · 32,816,500 shares of our common stock by the selling stockholders named in this prospectus, of which 11,408,078 shares may be issued upon exercise of warrants h

BNKL / Bionik Laboratories Corp. - SEC备案- 年度报告、委托书

基本统计

SEC Filings

SEC Filings (Chronological Order)